Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label and multi-center Phase 1b/2 study to evaluate the safety and
efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus
(HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with
lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).